title: Vismodegib in the treatment of advanced BCC.
abstract: Basal-cell carcinoma (BCC) is the most commonly diagnosed malignancy, comprising over 80 per thousand of non-melanoma skin cancers. Surgical excision is adequate treatment for most BCC's. Options are however limited for the minority of patients presenting with locally advanced inoperable or metastatic BCC. The Hedgehog signalling pathway is a critical driver in the pathogenesis of both sporadic and hereditary BCC. On 31st January 2012, based on a phase II clinical trial the US Food and Drug Administration approved Vismodegib (Erivedge, Roche) a first-in-class, small-molecule oral Hedgehog-inhibitor for the treatment of locally advanced inoperable and metastatic BCC. We present our experience treating the first Irish patient with this agent.
authors.forename: G M
authors.initials: GM
authors.lastname: O'Kane
authors.forename: T
authors.initials: T
authors.lastname: Lyons
authors.forename: I
authors.initials: I
authors.lastname: McDonald
authors.forename: N
authors.initials: N
authors.lastname: Mulligan
authors.forename: F J
authors.initials: FJ
authors.lastname: Moloney
authors.forename: D
authors.initials: D
authors.lastname: Murray
authors.forename: C M
authors.initials: CM
authors.lastname: Kelly
mesh_terms: D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D057176:Compassionate Use Trials; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; C538724:HhAntag691; D011725:Pyridines